Travere Therapeutics, Inc. Common Stock
TVTX
TVTX: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
moreShow TVTX Financials
Recent trades of TVTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TVTX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases Dec. 28, 2021
Federal grants, loans, and purchases
Followers on TVTX's company Twitter account
Number of mentions of TVTX in WallStreetBets Daily Discussion
Recent insights relating to TVTX
Recent picks made for TVTX stock on CNBC
ETFs with the largest estimated holdings in TVTX
Flights by private jets registered to TVTX